The clinicophatholgic report of antivirus therapy in patients with liver cirrhosis resulting from Hepatitis B
10.3760/cma.j.issn.1008-6315.2009.08.016
- VernacularTitle:肝炎肝硬化失代偿抗病毒治疗临床病理分析
- Author:
Zhenying ZHANG
;
Yaoping WANG
;
Sijie LI
- Publication Type:Journal Article
- Keywords:
Liver cirrhosis;
Adefovi;
Lamivudine
- From:Clinical Medicine of China
2009;25(8):828-830
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the clinicophatholgic benefits and safty of antivirus therapy in patients with liver cirrhosis resulting from hepatitis B.Methods 80 patients with HBV-ralated liver cirrhosis were divided into three groups by the histopathology of liver:group of lamivudine treated with lamivudine 100 mg once daily;Adefovir group treated with Adefovir 10 mg once daily;control group treated with liver protective treatment only.Liver and renal function,PTA and HBV DNA were regularly measured.The Child push-Turotte sore and histopathology wag compared before and after treatment.All courses of treatment were 36 weeks.Results The scores of Child Pugh-Turotte sore in groups of lamivudine and Adefovir were lowered sinificantly (3.9 and 2.1 respectively),the load of HBV-DNA was decreased also[(4.1±0.9) copies/ml and(2.8±1.0) copies/ml],liver inflammmation decreased by more than 2 scores and liver fiber was improved by more than one score,with obviously significant difference(P<0.05) as compared with control group.Conclusion Patients with HBV-related cirrhosis treated with lamivudine and adefovir for antivims are improved and antivirus is important and safe to those during cirrhosis decompensation.
